Linked Life Data

10389940

Source:http://linkedlifedata.com/resource/pubmed/id/10389940

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1999-9-30
pubmed:abstractText
Although Burkitt's lymphoma (BL) is a readily treated malignancy, recurrences, as well as disease arising in immunosuppressed patients, are notoriously resistant to conventional therapeutic approaches. The EBV is associated with a significant proportion of these lymphomas that evade immune surveillance through decreased expression of both viral and cellular antigens. Increasing the immunogenicity of BL cells may, therefore, represent a potentially beneficial therapeutic maneuver. Using in vitro models of EBV-transformed lymphoblastoid as well as BL cell lines, we demonstrate increased expression of genes coding for HLA class I and EBV latent proteins by the differentiation inducer phenylbutyrate (PB). The aromatic fatty acid also caused cytostasis associated with sustained declines in c-myc expression, a direct antitumor effect that was independent of the EBV status. We conclude, therefore, that differentiation therapy of BL with PB may lead to growth arrest with increased tumor immunogenicity in vivo. The findings may have clinical relevance because the in vitro activity has been observed with PB concentrations that are well tolerated and nonimmunosuppressive in humans, a desirable feature for the different patient populations afflicted with this disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1509-16
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10389940-Burkitt Lymphoma, pubmed-meshheading:10389940-Cell Differentiation, pubmed-meshheading:10389940-Cell Division, pubmed-meshheading:10389940-Cell Size, pubmed-meshheading:10389940-DNA, Viral, pubmed-meshheading:10389940-Dose-Response Relationship, Drug, pubmed-meshheading:10389940-Flow Cytometry, pubmed-meshheading:10389940-Gene Expression, pubmed-meshheading:10389940-Gene Expression Regulation, Viral, pubmed-meshheading:10389940-Herpesvirus 4, Human, pubmed-meshheading:10389940-Histocompatibility Antigens Class I, pubmed-meshheading:10389940-Humans, pubmed-meshheading:10389940-Phenylbutyrates, pubmed-meshheading:10389940-Tumor Cells, Cultured, pubmed-meshheading:10389940-Up-Regulation, pubmed-meshheading:10389940-Viral Matrix Proteins, pubmed-meshheading:10389940-Virus Activation
pubmed:year
1999
pubmed:articleTitle
Phenylbutyrate induces cell differentiation and modulates Epstein-Barr virus gene expression in Burkitt's lymphoma cells.
pubmed:affiliation
Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't